Omalizumab's effectiveness in severe allergic asthma and nasal polyps: a real-life study.

CONCLUSIONS: The treatment by omalizumab in SAA improves the associated CRSNP+ outcomes supporting the concept of the one airway disease.
PMID: 30931917 [PubMed - as supplied by publisher]

Source: Journal of Investigational Allergology and Clinical Immunology - March 31, 2019 Category: Allergy & Immunology Authors: Tiotiu A, Oster JP, Roux P, Nguyen Thi PL, Peiffer G, Bonniaud P, Dalphin JC, de Blay F Tags: J Investig Allergol Clin Immunol Source Type: research